JPMorgan's asset-management arm has successfully raised over $500 million for a new biotech venture-capital fund. The fund, managed by J.P. Morgan Life Sciences Private Capital, aims to invest in the burgeoning sector of weight-loss drugs and other life science startups. This marks the inaugural fundraising effort for the team within the investment banking giant, highlighting a significant commitment to advancing health care innovations and private biotechs.
🚨 Innovators take note! A fresh $500M for biotech $XBI CONGRATS to the JPM team! https://t.co/ScT4aMERSs
J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a wide range of private biotechs. https://t.co/IUqdQpYKu3
Five takeaways from my convo w/ steve squinto as JP Morgan closes its first $500M biotech fund — https://t.co/7xwhP6bz73
J.P. Morgan Life Sciences Private Capital, a small team within the investment banking giant, closed its first fundraising, bringing in more than $500 million to invest in life science startups.… https://t.co/QeLHEdMltN
JPMorgan raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs https://t.co/izAJAsnSt4
JPMorgan’s asset-management arm raises more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs https://t.co/nzGvhQzKUa